TAXUS Liberte DES Has Thinner Struts, More Flexibility
Boston Scientific Corp. offers its second-generation TAXUS Liberte Paclitaxel-Eluting Coronary Stent System, which has substantially thinner struts and a more flexible cell geometry for improved deliverability. It also has uniform strut distribution designed specifically for better drug elution.
The TAXUS Liberte was approved by the FDA in October 2008. The TAXUS Liberte stent was launched in Europe and other international markets in 2005.